“`html
Viking Therapeutics (VKTX) reported a loss of 81 cents per share for Q3 2025, exceeding the Zacks Consensus Estimate of a 70 cents loss, and significantly wider than the 22 cents loss in the same quarter last year. The company has no approved products and thus reported zero revenues.
Research and development expenses rose to $90.0 million from $22.8 million year-over-year, driven by increased costs for clinical studies and manufacturing. As of September 30, 2025, Viking Therapeutics has $715 million in cash and short-term investments, down from $808 million as of June 30, 2025.
Viking is advancing its VK2735 obesity drug candidate through two phase III studies, targeting enrollment completion by the end of 2025 for VANQUISH-1 and Q1 2026 for VANQUISH-2. A new maintenance study has also been initiated, with results expected by mid-2026.
“`
